Literature DB >> 16721052

The TRIP-Br family of transcriptional regulators is essential for the execution of cyclin E-mediated cell cycle progression.

Khe Guan Sim1, Jit Kong Cheong, Stephen I-Hong Hsu.   

Abstract

The G1 D-type cyclins, in conjunction with cyclin-dependent kinases Cdk4 and Cdk6, play key roles in the execution of mitogen-induced cellular proliferation. TRIP-Br1, a member of the TRIP-Br family of transcriptional regulators, has been implicated in the regulation of Cdk4/cyclin D activity. To further elucidate the functional role(s) of the TRIP-Br proteins in mitogenic signaling, we have developed the synthetic DNA enzymes E-Br1 and E-Br2 to specifically knock down the serum-inducible expression of TRIP-Br1 and TRIP-Br2, respectively, in WI-38 human fibroblasts in culture, as well as generated TRIP-Br2 null primary embryonic fibroblasts from a novel TRIP-Br2 knockout mouse model. Both strategies consistently reveal that ablation of TRIP-Br1 or TRIP-Br2 expression disrupts mitogenic signaling in a manner that suppresses serum-induced cyclin E expression, S-phase entry and cellular proliferation. We conclude that both TRIP-Br1 and TRIP-Br2 are required for proper transduction of mitogenic signals and execution of serum-inducible cell cycle progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721052     DOI: 10.4161/cc.5.10.2797

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  8 in total

1.  Transcriptome Profiling of the Virus-Induced Innate Immune Response in Pteropus vampyrus and Its Attenuation by Nipah Virus Interferon Antagonist Functions.

Authors:  Nicole B Glennon; Omar Jabado; Michael K Lo; Megan L Shaw
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

2.  Uncovering molecular biomarkers that correlate cognitive decline with the changes of hippocampus' gene expression profiles in Alzheimer's disease.

Authors:  Martín Gómez Ravetti; Osvaldo A Rosso; Regina Berretta; Pablo Moscato
Journal:  PLoS One       Date:  2010-04-13       Impact factor: 3.240

3.  Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance.

Authors:  Chong Wee Liew; Jeremie Boucher; Jit Kong Cheong; Cecile Vernochet; Ho-Jin Koh; Cristina Mallol; Kristy Townsend; Dominique Langin; Dan Kawamori; Jiang Hu; Yu-Hua Tseng; Marc K Hellerstein; Stephen R Farmer; Laurie Goodyear; Alessandro Doria; Matthias Blüher; Stephen I-Hong Hsu; Rohit N Kulkarni
Journal:  Nat Med       Date:  2013-01-06       Impact factor: 53.440

4.  Regulation of CDK4.

Authors:  Laurence Bockstaele; Katia Coulonval; Hugues Kooken; Sabine Paternot; Pierre P Roger
Journal:  Cell Div       Date:  2006-11-08       Impact factor: 5.130

5.  Nutrient/serum starvation derived TRIP-Br3 down-regulation accelerates apoptosis by destabilizing XIAP.

Authors:  Chengping Li; Samil Jung; Soonduck Lee; Dongjun Jeong; Young Yang; Keun-Il Kim; Jong-Seok Lim; Chung-Il Cheon; Changjin Kim; Young-Sook Kang; Myeong-Sok Lee
Journal:  Oncotarget       Date:  2015-04-10

6.  The complex of TRIP-Br1 and XIAP ubiquitinates and degrades multiple adenylyl cyclase isoforms.

Authors:  Wenbao Hu; Xiaojie Yu; Zhengzhao Liu; Ying Sun; Xibing Chen; Xin Yang; Xiaofen Li; Wai Kwan Lam; Yuanyuan Duan; Xu Cao; Hermann Steller; Kai Liu; Pingbo Huang
Journal:  Elife       Date:  2017-06-28       Impact factor: 8.140

Review 7.  Prognostic and Clinicopathological Significance of SERTAD1 in Various Types of Cancer Risk: A Systematic Review and Retrospective Analysis.

Authors:  Raj Kumar Mongre; Samil Jung; Chandra Bhushan Mishra; Beom Suk Lee; Shikha Kumari; Myeong-Sok Lee
Journal:  Cancers (Basel)       Date:  2019-03-08       Impact factor: 6.639

8.  TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors.

Authors:  Jit Kong Cheong; Lakshman Gunaratnam; Zhi Jiang Zang; Christopher M Yang; Xiaoming Sun; Susan L Nasr; Khe Guan Sim; Bee Keow Peh; Suhaimi Bin Abdul Rashid; Joseph V Bonventre; Manuel Salto-Tellez; Stephen I Hsu
Journal:  J Transl Med       Date:  2009-01-20       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.